26M Stock Overview
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mirati Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.30 |
| 52 Week High | US$59.46 |
| 52 Week Low | US$25.13 |
| Beta | 0.77 |
| 1 Month Change | 0.95% |
| 3 Month Change | 2.74% |
| 1 Year Change | 22.25% |
| 3 Year Change | -69.72% |
| 5 Year Change | -1.55% |
| Change since IPO | 247.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26M | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -4.3% | -2.5% |
| 1Y | 22.2% | -19.4% | -0.4% |
Return vs Industry: 26M exceeded the German Biotechs industry which returned -26.5% over the past year.
Return vs Market: 26M exceeded the German Market which returned -1.3% over the past year.
Price Volatility
| 26M volatility | |
|---|---|
| 26M Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 26M has not had significant price volatility in the past 3 months.
Volatility Over Time: 26M's weekly volatility has decreased from 10% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 587 | Chuck Baum | www.mirati.com |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Mirati Therapeutics, Inc. Fundamentals Summary
| 26M fundamental statistics | |
|---|---|
| Market cap | €3.79b |
| Earnings (TTM) | -€668.10m |
| Revenue (TTM) | €35.15m |
107.8x
P/S Ratio-5.7x
P/E RatioIs 26M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26M income statement (TTM) | |
|---|---|
| Revenue | US$38.19m |
| Cost of Revenue | US$510.48m |
| Gross Profit | -US$472.29m |
| Other Expenses | US$253.59m |
| Earnings | -US$725.88m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.35 |
| Gross Margin | -1,236.66% |
| Net Profit Margin | -1,900.65% |
| Debt/Equity Ratio | 0% |
How did 26M perform over the long term?
See historical performance and comparison